Prof Diether Lambrechts (Angiopredict partner VIB) recently presented at the 9th International Experts Panel Meeting "ANTIANGIOGENETIC THERAPIES IN NSCLC:REALITY AND HOPES" in Sperlonga, Italy, (May 8, 2015). The title of Prof Lambrechts presentation was "Biomarkers for antiangiogenetics".

 Prof Lambrechts was also one of the authors behind a recent publication in Angiogenesis: "Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy" (S. de Haas et al.). Angiogenesis 2014 Oct;17(4):909-20, D.O.I. : 10.1007/s10456-014-9438-1. To access the article click here http://link.springer.com/article/10.1007%2Fs10456-014-9438-1